Citius Oncology (NASDAQ:CTOR) Announces Quarterly Earnings Results, Misses Estimates By $0.26 EPS

Posted by George Bondi on May 17th, 2026

Citius Oncology (NASDAQ:CTOR – Get Free Report) posted its earnings results on Friday. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.26), FiscalAI reports. The company had revenue of $1.67 million during the quarter, compared to analysts’ expectations of $7.00 million.

Citius Oncology Stock Down 2.1%

Shares of CTOR traded down $0.02 during mid-day trading on Friday, hitting $0.96. 25,246 shares of the company’s stock were exchanged, compared to its average volume of 113,707. The stock’s 50-day moving average is $0.80 and its 200-day moving average is $1.07. The company has a market cap of $85.04 million, a price-to-earnings ratio of -2.05 and a beta of 3.56. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.32 and a current ratio of 0.83. Citius Oncology has a fifty-two week low of $0.49 and a fifty-two week high of $6.19.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CTOR. Citadel Advisors LLC purchased a new stake in Citius Oncology during the 3rd quarter worth about $36,000. Bank of America Corp DE boosted its stake in shares of Citius Oncology by 5,256.9% in the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock valued at $37,000 after buying an additional 8,411 shares during the period. OMERS ADMINISTRATION Corp acquired a new position in shares of Citius Oncology during the fourth quarter worth about $104,000. Geode Capital Management LLC grew its position in shares of Citius Oncology by 31.6% during the fourth quarter. Geode Capital Management LLC now owns 220,047 shares of the company’s stock worth $220,000 after buying an additional 52,875 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Citius Oncology during the second quarter worth approximately $465,000. 70.52% of the stock is currently owned by hedge funds and other institutional investors.

About Citius Oncology

(Get Free Report)

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.